Treatment progress of pains caused by transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy in hepatocellular carcinoma
- JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY Vol. 33, Issue 2, Pages: 170-174(2024)
- 作者机构：
重庆医科大学附属第二医院麻醉科，重庆 400010
- 作者简介：
- 基金信息：
DOI：10.11659/jjssx.03E023034
CLC： R441.1Published：25 February 2024，
Received：07 March 2023，
扫 描 看 全 文
贾贵鎣,黄燕,黄河等.肝癌肝动脉化疗栓塞及肝动脉灌注化疗术后疼痛的治疗进展[J].局解手术学杂志,2024,33(02):170-174.
JIA Gui-ying,HUANG Yan,HUANG He,et al.Treatment progress of pains caused by transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy in hepatocellular carcinoma[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2024,33(02):170-174.
贾贵鎣,黄燕,黄河等.肝癌肝动脉化疗栓塞及肝动脉灌注化疗术后疼痛的治疗进展[J].局解手术学杂志,2024,33(02):170-174. DOI： 10.11659/jjssx.03E023034.
JIA Gui-ying,HUANG Yan,HUANG He,et al.Treatment progress of pains caused by transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy in hepatocellular carcinoma[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2024,33(02):170-174. DOI： 10.11659/jjssx.03E023034.
摘要
肝动脉化疗栓塞（TACE）及肝动脉灌注化疗（HAIC）等转化治疗是目前将不可切除晚期肝癌降期转化为可切除肝癌的主要治疗方法，不仅可以有效提高患者生存率，同时可为患者提供肝移植的机会。然而，疼痛为肝癌TACE和HAIC治疗的主要并发症，TACE术后腹痛的发生率为19.3％～71.2％，HAIC治疗过程中近64.6%的患者会出现不同程度的疼痛，严重影响患者的生活质量，缩短患者的生存期。目前，TACE和HAIC引起疼痛的发生机制尚不明确，可能与栓塞剂阻塞肿瘤供血动脉后局部肝组织肿胀、肝组织被膜压力增高或肿块包膜被牵拉、栓塞剂与抗肿瘤药物对肝动脉的化学刺激、邻近正常脏器的误栓及肠管缺血所致的内脏痛觉敏化有关。疼痛的干预措施主要有两种，一种是利多卡因、阿片类药物、非甾体抗炎药物及糖皮质激素等干预措施；另一种是腕踝针、中药汤剂等其他干预措施，但治疗效果参差不齐。本文就肝癌TACE及HAIC治疗所致疼痛情况及治疗现状进行综述，以期为其临床治疗提供参考。
Abstract
Conversion therapy such as transcatheter arterial chemoembolization （TACE） and hepatic arterial infusion chemotherapy （HAIC） is the main treatment method to transform unresectable advanced liver cancer into resectable liver cancer， which can not only effectively increase the survival rate of patients， but also provide patients with the opportunity of liver transplantation. However， pain is a major complication of TACE and HAIC in the treatment of liver cancer， and the incidence of abdominal pain after TACE is from 19.3% to 71.2%， and nearly 64.6% of patients have different degrees of pain during HAIC， which seriously affects the quality of life of patients and shortens their survival time. At present， the mechanism of pains caused by TACE and HAIC is not clear， and it may be related to local liver tissue swelling after embolic agents block the tumor blood supply artery， increased pressure in the liver tissue envelope or traction of the mass capsule， chemical stimulation of the hepatic artery by embolic agents and antineoplastic drugs， thrombosis adjacent to the normal organs， and visceral pain sensitization caused by intestinal ischemia. There are two main intervention measures for pain， one of which is lidocaine， opioids， non-steroidal anti-inflammatory drugs and glucocorticoids， and the other is wrist and ankle acupuncture and traditional Chinese medicine decoction， but their treatment effects are uneven. This article summarizes the status and treatment of pain caused by TACE and HAIC therapies for liver cancer， in order to provide reference for its clinical treatment.
关键词
肝动脉化疗栓塞肝动脉灌注化疗疼痛肝癌
Keywords
transcatheter arterial chemoembolizationhepatic arterial infusion chemotherapypainliver cancer
references
Sung H，Ferlay J，Siegel RL，et al.Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin，2021，71（3）：209-249.doi：10.3322/caac.21660http://dx.doi.org/10.3322/caac.21660.
中华预防医学会肝胆胰疾病预防与控制专业委员会，中国抗癌协会肝癌专业委员会，北京医学会外科学分会肝脏学组，等.基于免疫联合靶向方案的晚期肝细胞癌转化治疗中国专家共识（2021版）［J］.中华肝胆外科杂志，2021，27（4）：241-251.doi：10.3760/cma.j.cn113884-20210415-00138http://dx.doi.org/10.3760/cma.j.cn113884-20210415-00138.
Zhou J，Sun H，Wang Z，et al.Guidelines for the diagnosis and treatment of hepatocellular carcinoma （2019 Edition）［J］.Liver Cancer，2020，9（6）：682-720.
European Association For the Study of the Liver.EASL clinical practice guidelines：management of hepatocellular carcinoma［J］.J Hepatol，2018，69（1）：182-236.
Finn RS，Ikeda M，Zhu AX，et al.Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma［J］.J Clin Oncol，2020，38（26）：2960-2970.
Forner A，Reig M，Bruix J.Hepatocellular carcinoma［J］.Lancet，2018，391（10127）：1301-1314.doi：10.1016/S0140-6736（18）30010-2http://dx.doi.org/10.1016/S0140-6736（18）30010-2.
Lau WY，Lai EC.Salvage surgery following downstaging of unresectable hepatocellular carcinoma--a strategy to increase resectability［J］.Ann Surg Oncol，2007，14（12）：3301-3309.doi：10.1245/s10434-007-9549-7http://dx.doi.org/10.1245/s10434-007-9549-7.
史广龙，徐学东，黄 瑞，等.调强放射治疗联合卡瑞利珠单抗治疗中晚期肝细胞肝癌的临床研究［J］.局解手术学杂志，2024，33（1）：43-46.doi：10.11659/jjssx.05E023051http://dx.doi.org/10.11659/jjssx.05E023051.
国家卫生健康委办公厅.原发性肝癌诊疗指南（2022年版）［J］.临床肝胆病杂志，2022，38（2）：288-303.doi：10.3969/j.issn.1001-5256.2022.02.009http://dx.doi.org/10.3969/j.issn.1001-5256.2022.02.009.
Golfieri R，Giampalma E，Renzulli M，et al.Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma［J］.Br J Cancer，2014，111（2）：255-264.doi：10.1038/bjc.2014.199http://dx.doi.org/10.1038/bjc.2014.199.
Lv N，Kong Y，Mu L，et al.Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma：a prospective randomized trial［J］.Eur Radiol，2016，26（10）：3492-3499.doi：10.1007/s00330-016-4207-8http://dx.doi.org/10.1007/s00330-016-4207-8.
Cheng X，Sun P，Hu QG，et al.Transarterial （chemo） embolization for curative resection of hepatocellular carcinoma：a systematic review and meta-analyses［J］.J Cancer Res Clin Oncol，2014，140（7）：1159-1170.doi：10.1007/s00432-014-1677-4http://dx.doi.org/10.1007/s00432-014-1677-4.
Zeng K，Dong HJ，Chen HY，et al.Wrist-ankle acupuncture for pain after transcatheter arterial chemoembolization in patients with liver cancer：a randomized controlled trial［J］.Am J Chin Med，2014，42（2）：289-302.doi：10.1142/S0192415X14500190http://dx.doi.org/10.1142/S0192415X14500190.
Zhou B，Wang J，Yan Z，et al.Liver cancer：effects，safety，and cost-effectiveness of controlled-release oxycodone for pain control after TACE［J］.Radiology，2012，262（3）：1014-1021.doi：10.1148/radiol.11110552http://dx.doi.org/10.1148/radiol.11110552.
Prajapati HJ，Rafi S，El-Rayes BF，et al.Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization［J］.J Vasc Interv Radiol，2012，23（10）：1286-1293.e1.doi：10.1016/j.jvir.2012.07.003http://dx.doi.org/10.1016/j.jvir.2012.07.003.
Molgaard CP，Teitelbaum GP，Pentecost MJ，et al.Intraarterial administration of lidocaine for analgesia in hepatic chemoembolization［J］.J Vasc Interv Radiol，1990，1（1）：81-85.doi：10.1016/s1051-0443（90）72508-0http://dx.doi.org/10.1016/s1051-0443（90）72508-0.
Lee SH，Hahn ST，Park SH.Intraarterial lidocaine administration for relief of pain resulting from transarterial chemoembolization of hepatocellular carcinoma：its effectiveness and optimal timing of administration［J］.Cardiovasc Intervent Radiol，2001，24（6）：368-371.doi：10.1007/s00270-001-0073-zhttp://dx.doi.org/10.1007/s00270-001-0073-z.
周德贤，甘子明，张盼盼，等.缺血性内脏痛模型大鼠脊髓背角NMDA受体NR2B亚单位的表达［J］.新疆医科大学学报，2013，36（5）：618-622.doi：10.3969/j.issn.1009-5551.2013.05.013http://dx.doi.org/10.3969/j.issn.1009-5551.2013.05.013.
Bian LF，Zhao XH，Gao BL，et al.Predictive model for acute abdominal pain after transarterial chemoembolization for liver cancer［J］.World J Gastroenterol，2020，26（30）：4442-4452.doi：10.3748/wjg.v26.i30.4442http://dx.doi.org/10.3748/wjg.v26.i30.4442.
Yang Y，Chen S，Yan Z，et al.Construction and validation of prediction model of severe abdominal pain post-transarterial chemoembolization in patients with HBV-associated primary liver cancer［J］.Comput Math Methods Med，2022，2022：5203166.doi：10.1155/2022/5203166http://dx.doi.org/10.1155/2022/5203166.
Benzakoun J，Ronot M，Lagadec M，et al.Risks factors for severe pain after selective liver transarterial chemoembolization［J］.Liver Int，2017，37（4）：583-591.doi：10.1111/liv.13235http://dx.doi.org/10.1111/liv.13235.
Hartnell GG，Gates J，Stuart K，et al.Hepatic chemoembolization：effect of intraarterial lidocaine on pain and postprocedure recovery［J］.Cardiovasc Intervent Radiol，1999，22（4）：293-297.doi：10.1007/s002709900391http://dx.doi.org/10.1007/s002709900391.
Molgaard CP，Teitelbaum GP，Pentecost MJ，et al.Intraarterial administration of lidocaine for analgesia in hepatic chemoembolization［J］.J Vasc Interv Radiol，1990，1（1）：81-85.doi：10.1016/s1051-0443（90）72508-0http://dx.doi.org/10.1016/s1051-0443（90）72508-0.
Romano M，Giojelli A，Tamburrini O，et al.Chemoembolization for hepatocellular carcinoma：effect of intraarterial lidocaine in peri- and post-procedural pain and hospitalization［J］.Radiol Med，2003，105（4）：350-355.
Fiorentini G，Aliberti C，Benea G，et al.TACE of liver metastases from colorectal cancer adopting irinotecan-eluting beads：beneficial effect of palliative intra-arterial lidocaine and post-procedure supportive therapy on the control of side effects［J］.Hepatogastroenterology，2008，55（88）：2077-2082.
Wang LZ，Hu XX，Shen XC，et al.Intraarterial lidocaine administration for pain control by water-in-oil technique in transarterial chemoembolization：in vivo and randomized clinical trial［J］.J Hepatocell Carcinoma，2021，8：1221-1232.doi：10.2147/JHC.S331779http://dx.doi.org/10.2147/JHC.S331779.
Narayanan G，Barbery K，Suthar R，et al.Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer［J］.Anticancer Res，2013，33（5）：2077-2083.
Guo JG，Zhao LP，Rao YF，et al.Novel multimodal analgesia regimen improves post-TACE pain in patients with hepatocellular carcinoma［J］.Hepatobiliary Pancreat Dis Int，2018，17（6）：510-516.doi：10.1016/j.hbpd.2018.08.001http://dx.doi.org/10.1016/j.hbpd.2018.08.001.
Lyu N，Kong Y，Li X，et al.Effect and safety of prophylactic parecoxib for pain control of transarterial chemoembolization in liver cancer：a single-center，parallel-group，randomized trial［J］.J Am Coll Radiol，2022，19（1 Pt A）：61-70.doi：10.1016/j.jacr.2021.09.029http://dx.doi.org/10.1016/j.jacr.2021.09.029.
Zhou ZG，Chen JB，Qiu HB，et al.Parecoxib prevents complications in hepatocellular carcinoma patients receiving hepatic transarterial chemoembolization：a prospective score-matched cohort study［J］.Oncotarget，2016，7（19）：27938-27945.doi：10.18632/oncotarget. 8560http://dx.doi.org/10.18632/oncotarget.8560.
Yinglu F，Changquan L，Xiaofeng Z，et al.A new way：alleviating postembolization syndrome following transcatheter arterial chemoembolization［J］.J Altern Complement Med，2009，15（2）：175-181.doi：10.1089/acm.2008.0093http://dx.doi.org/10.1089/acm.2008.0093.
Lu H，Zheng C，Liang B，et al.Efficacy and safety analysis of dexamethasone-lipiodol emulsion in prevention of post-embolization syndrome after TACE：a retrospective analysis［J］.BMC Gastroenterol，2021，21（1）：256.doi：10.1186/s12876-021-01839-whttp://dx.doi.org/10.1186/s12876-021-01839-w.
Yang H，Seon J，Sung PS，et al.Dexamethasone prophylaxis to alleviate postembolization syndrome after transarterial chemoembolization for hepatocellular carcinoma：a randomized，double-blinded，placebo-controlled study［J］.J Vasc Interv Radiol，2017，28（11）：1503-1511.e2.doi：10.1016/j.jvir.2017.07.021http://dx.doi.org/10.1016/j.jvir.2017.07.021.
Sainamthip P，Kongphanich C，Prasongsook N，et al.Single dose dexamethasone prophylaxis of postembolisation syndrome after chemoembolisation in hepatocellular carcinoma patient：a randomised，double-blind，placebo-controlled study［J］.World J Clin Cases，2021，9（30）：9059-9069.doi：10.12998/wjcc.v9.i30.9059http://dx.doi.org/10.12998/wjcc.v9.i30.9059.
Kogut MJ，Chewning RH，Harris WP，et al.Postembolization syndrome after hepatic transarterial chemoembolization：effect of prophylactic steroids on postprocedure medication requirements［J］.J Vasc Interv Radiol，2013，24（3）：326-331.doi：10.1016/j.jvir. 2012.11.019http://dx.doi.org/10.1016/j.jvir.2012.11.019.
Xu L，Wang S，Zhuang L，et al.Jian Pi Li Qi decoction alleviated postembolization syndrome following transcatheter arterial chemoembolization for hepatocellular carcinoma：a randomized，double-blind，placebo-controlled trial［J］.Integr Cancer Ther，2016，15（3）：349-357.doi：10.1177/1534735415617020http://dx.doi.org/10.1177/1534735415617020.
宋文玲，罗耀昌，胡朋，等.穴位敷贴王不留行籽按摩对肝癌介入术后栓塞综合征的效果［J］.介入放射学杂志，2022，31（3）：259-262.doi：10.3969/j.issn.1008-794X.2022.03.010http://dx.doi.org/10.3969/j.issn.1008-794X.2022.03.010.
何佳枫，戚龙菊，余静，等.居家有氧运动对肝癌肝动脉化疗栓塞术患者症状群的干预研究［J］.中国康复医学杂志，2022，37（4）：470-475.doi：10.3969/j.issn.1001-1242.2022.04.006http://dx.doi.org/10.3969/j.issn.1001-1242.2022.04.006.
骆亿，丁国善，董家勇.不可切除晚期肝癌的转化治疗策略研究进展［J］.解放军医学杂志，2022，47（7）：731-738.doi：10.11855/j.issn.0577-7402.2022.07.0731http://dx.doi.org/10.11855/j.issn.0577-7402.2022.07.0731.
Long GB，Xiao CW，Zhao XY，et al.Effects of hepatic arterial infusion chemotherapy in the treatment of hepatocellular carcinoma：a meta-analysis［J］.Medicine （Baltimore），2020，99（26）：e20745.doi：10.1097/MD.0000000000020745http://dx.doi.org/10.1097/MD.0000000000020745.
Wu Z，Guo W，Chen S，et al.Determinants of pain in advanced HCC patients recieving hepatic artery infusion chemotherapy［J］.Invest New Drugs，2021，39（2）：394-399.doi：10.1007/s10637-020-01009-xhttp://dx.doi.org/10.1007/s10637-020-01009-x.
Hsu SJ，Xu X，Chen MP，et al.Hepatic arterial infusion chemotherapy with modified FOLFOX as an alternative treatment option in advanced hepatocellular carcinoma patients with failed or unsuitability for transarterial chemoembolization［J］.Acad Radiol，2021，28 Suppl 1：S157-S166.doi：10.1016/j.acra.2021.01.024http://dx.doi.org/10.1016/j.acra.2021.01.024.
Liu B，Zhu X，Gao S，et al.Safety and efficacy of hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin post-transarterial chemoembolization for unresectable hepatocellular carcinoma［J］.J Interv Med，2019，2（2）：91-96.doi：10.1016/j.jimed.2019.07.006http://dx.doi.org/10.1016/j.jimed.2019.07.006.
Gao S，Zhang PJ，Guo JH，et al.Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients［J］.World J Gastroenterol，2015，21（36）：10443-10452.doi：10.3748/wjg.v21.i36. 10443http://dx.doi.org/10.3748/wjg.v21.i36.10443.
Boilève A，De Cuyper A，Larive A，et al.Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases［J］.Eur J Cancer，2020，138：89-98.doi：10.1016/j.ejca.2020.07.022http://dx.doi.org/10.1016/j.ejca.2020.07.022.
Xu Y，Fu S，Mao Y，et al.Efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed cell death protein-1 antibody and lenvatinib for advanced hepatocellular carcinoma［J］.Front Med （Lausanne），2022，9：919069.doi：10.3389/fmed. 2022.919069http://dx.doi.org/10.3389/fmed.2022.919069.
Feng AW，Guo JH，Gao S，et al.A randomized phase Ⅱ trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases［J］.Front Oncol，2022，12：913017.doi：10.3389/fonc.2022.913017http://dx.doi.org/10.3389/fonc.2022.913017.
Bruno PM，Liu Y，Park GY，et al.A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress［J］.Nat Med，2017，23（4）：461-471.doi：10.1038/nm.4291http://dx.doi.org/10.1038/nm.4291.
Dzodic R，Gomez-Abuin G，Rougier P，et al.Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration：comparative results with cisplatin using a rabbit VX2 tumor model［J］.Anticancer Drugs，2004，15（6）：647-650.doi：10.1097/01.cad.0000131684.06390.fehttp://dx.doi.org/10.1097/01.cad.0000131684.06390.fe.
Kerbage F，Grinda T，Smolenschi C，et al.Is intra-arterial hepatic chemotherapy painful？［J］.Support Care Cancer，2020，28（10）：4585-4587.doi：10.1007/s00520-020-05560-4http://dx.doi.org/10.1007/s00520-020-05560-4.
Sałat K.Chemotherapy-induced peripheral neuropathy-part 2：focus on the prevention of oxaliplatin-induced neurotoxicity［J］.Pharmacol Rep，2020，72（3）：508-527.doi：10.1007/s43440-020-00106-1http://dx.doi.org/10.1007/s43440-020-00106-1.
0
Views
3
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
